市場調査レポート

ハイスループットスクリーニング(HTS):効果的戦略、革新的技術、および改良型アッセイの使用

High Throughput Screening 2012: Improved Strategies, Adaptive Technologies and Enhanced Assays

発行 HighTech Business Decisions 商品コード 206942
出版日 ページ情報 英文 850 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
ハイスループットスクリーニング(HTS):効果的戦略、革新的技術、および改良型アッセイの使用 High Throughput Screening 2012: Improved Strategies, Adaptive Technologies and Enhanced Assays
出版日: 2012年08月07日 ページ情報: 英文 850 Pages
概要

当レポートでは、ハイスループットスクリーニング(HTS)市場の規模、成長見通し、参入企業、ユーザー戦略と技術動向などについて、詳細なデータに基づき分析し、概略下記の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 調査方法、定義、略語

第3章 ハイスループットスクリーニング:市場概要

  • ハイスループットスクリーニング市場の特徴
    • ハイスループットスクリーニングの成功
    • ハイスループットスクリーニング製品とサービス
    • 市場促進因子
    • サプライヤーと買収
  • 市場規模の特定
    • 創薬への投資
    • ハイスループットスクリーニング研究所数予測
    • ハイスループットスクリーニング研究所の支出に基づく市場予測
    • サプライヤー収益に基づく市場予測
    • ハイスループットスクリーニング製品・サービスのための市場規模予測
    • 地域別市場規模
  • 市場の成長
  • ハイスループットスクリーニング市場の機会
    • 顧客要件
    • サプライヤー向け機会

第4章 ハイスループットスクリーニング研究所業務分析

  • 回答者企業と非商用研究所
    • 所在地
    • 研究所従業員数
    • 研究所としての年数
    • 調査回答者役職
  • 機関と戦略
    • 回答者数
    • 研究所の種類
    • ハイスループットスクリーニング発見活動
    • ハイスループットスクリーニングの創薬への統合
    • ハイスループットスクリーニング業務で発生する主な変化
    • アジアへの拡充またはアウトソース計画
    • より効果的なスクリーニング業務の重要因子
    • 学術スクリーニング機関の影響
    • 主要設備サプライヤー
  • ハイスループットスクリーニングの目標
  • スループットと化合物
  • 創薬のためのアッセイ
  • 多重化
  • 細胞・細胞ベースアッセイ
  • ハイスループットスクリーニングとADME毒物検査
  • マイクロプレートとその他のフォーマット
  • 検出技術
  • データの取り扱い
  • アウトソーシングと提携
  • 予算
  • 創薬におけるハイスループットスクリーニングの成功
  • ハイスループットスクリーニングのための新規有望ツール

第5章 ハイスループットスクリーニング製品およびサービスを提供する企業分析

  • サプライヤー
    • 調査に参加したサプライヤー
    • 主な買収と提携
    • サプライヤーの種類
    • 製品・サービス
    • ハイスループットスクリーニング以外の製品提供
    • 組織変更
  • 顧客および顧客要件
    • サプライヤーによる顧客変化の観察
    • 顧客が要求したツールやソリューション
    • 顧客がサプライヤーを選ぶ理由
    • 顧客が製品を選ぶ理由
    • 顧客の創薬アプローチの格付け
  • ハイスループットスクリーニング製品動向の観察
  • マーケティング
    • 新規顧客獲得方法
    • 販売プロセスの評価
    • 最大の競合力
    • 大手設備サプライヤー
  • 営業および業界の成長
  • 将来動向
    • 大きく成長が見込める分野
    • 主な技術
    • 創薬のアウトソーシング
    • ハイスループットスクリーニング市場全体
    • 将来の創薬

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Abstract

HighTech Business Decisions conducted the market research and wrote the report, High Throughput Screening 2012: Improved Screening, Adapted Technologies and Enhance Assays, to provide a comprehensive market analysis of the high throughput screening (HTS) market worldwide. The research was specifically designed to understand HTS users' perceptions, motivations, current practices, and future plans in regards to targets, target types, assays, assay development, cell-based assays, HCS, detection modes, microplate formats, outsourcing, budgets, and other issues impacting current HTS operations. The complete analysis, based on both user and supplier primary research, includes market size and growth, major players, user strategies and requirements, trends and technologies, and users' future plans. In-depth data collected from both users and suppliers allow for an objective and thorough analysis. We thank the 67 respondents from pharmaceutical, biotechnology, academic, and institute HTS laboratories, and HTS supplier companies, who took the time to share their insights, opinions, and future plans with us. We thank our sponsoring companies, who supported this project with their ideas, suggestions, and funding for the first few months of this five-month project.

The following analysts and staff made important contributions to this research and report:

Analysts

  • Jennifer Hartigan, Ph.D. - Respondent interviews and analysis
  • Helen Nicely, Ph.D. - Respondent interviews
  • Lynne Sopchak, Ph.D. - Respondent interviews

We hope that our clients obtain significant value from this report to help ensure the success of their future business.

William P. Downey, MBA
President

This report is Copyright protected by HighTech Business Decisions. All rights reserved. Printed and bound in the United States of America. Neither this report, nor parts of it, may be reproduced without written permission from HighTech Business Decisions.

HighTech Business Decisions has exercised due care in compiling this report, which is based on information submitted by individual companies. The company interview write-ups and information contained in this report are not intended to be a complete description of any one company, but a paraphrased synopsis of interviews conducted with these companies in October, November and December of 2009, combined with submitted material. The publishers have taken due care to ensure the accuracy of this information, but shall not be held liable for any consequential damages arising from the material in this report.

Table of Contents

Chapter 1: EXECUTIVE SUMMARY

  • 1.1 Introduction
  • 1.2 Overall Market Evaluation
    • 1.2.1 HTS Market Overview
    • 1.2.2 Market Drivers
    • 1.2.3 The HTS Market Size
    • 1.2.4 HTS Market Growth
  • 1.3 Summary of Users' Activities
    • 1.3.1 Current Environment's Effect on Drug Screening
    • 1.3.2 Drug Discovery Activities Performed by HTS Labs
    • 1.3.3 Targets
    • 1.3.4 Use of Assays and Assay Detection
    • 1.3.5 Importance of Phenotypic Screens
    • 1.3.6 Microplates
    • 1.3.7 Current and Planned Use of HCS Technologies
    • 1.3.8 Trends That Will Shape HTS
  • 1.4 Summary of Suppliers' Capabilities
    • 1.4.1 Suppliers' Observations on Changes
    • 1.4.2 Assay Development Focus
    • 1.4.3 Suppliers' Observations on Major Technology Trends

Chapter 2: METHODOLOGY, DEFINITIONS, AND ACRONYMS

  • 2.1 Research Objectives
  • 2.2 Research Methodology
  • 2.3 Definitions
  • 2.4 Acronyms

Chapter 3: HIGH THROUGHPUT SCREENING: MARKET OVERVIEW

  • 3.1 Characteristics of the HTS Market
    • 3.1.1 The Success of HTS
    • 3.1.2 HTS Products and Services
    • 3.1.3 Market Drivers
    • 3.1.4 Suppliers and Acquisitions
  • 3.2 Determination of Market Size
    • 3.2.1 Investment in Drug Discovery
    • 3.2.2 Estimate of the Number of HTS Laboratories Worldwide
    • 3.2.3 HTS Market Estimate Based on HTS Lab Spending
    • 3.2.4 HTS Market Estimate Based on Suppliers' Revenues
    • 3.2.5 Estimate of Market Size for HTS Products & Services
    • 3.2.6 Size of the Market by Region
  • 3.3 Market Growth
    • 3.3.1 HTS Market Growth Estimates
  • 3.4 Opportunities in the HTS Marketplace
    • 3.4.1 Customer Requirements
    • 3.4.2 Areas of Opportunity for Suppliers

Chapter 4: ANALYSIS OF HTS LABORATORY OPERATIONS

  • 4.1 Respondent Companies
    • 4.1.1 Locations
    • 4.1.2 Number of Employees in HTS Laboratories
    • 4.1.3 Number of Years as an HTS Laboratory
    • 4.1.4 Titles of Survey Respondents
  • 4.2 Organization and Strategy
    • 4.2.1 Number of Respondents' HTS Laboratories
    • 4.2.2 HTS Discovery Activities
    • 4.2.3 Integration of Screening within Drug Discovery
    • 4.2.4 Current Environment's Effect on Drug Screening Activities
    • 4.2.5 Biologics Screening
  • 4.3 HTS Targets
    • 4.3.1 Number of Targets Screened
    • 4.3.2 Target Types
  • 4.4 Throughput and Compounds
    • 4.4.1 Current and Future Throughput for Primary Screening
    • 4.4.2 Current/Future Throughput for Secondary Screening
    • 4.4.3 Current and Future Throughput for HCS
    • 4.4.4 Number of Compounds Tested in Primary Screens
    • 4.4.5 Number of Compounds Tested in Secondary Screens
    • 4.4.6 Number of Compounds Tested in HCS
    • 4.4.7 Types of Libraries Used for Primary Screening
    • 4.4.8 Size of Compound Libraries
    • 4.4.9 Minimum Deck Size for Primary Screening
    • 4.4.10 Change in Small Molecule HTS Programs
    • 4.4.11 Changes in the Importance of Compound Profiling
    • 4.4.12 Use of Compound Profiling
  • 4.5 Assays for Drug Discovery
    • 4.5.1 Current/Future Use of Assay Types in Primary Screening
    • 4.5.2 Use of Assay Types in Target Validation, Secondary Screening and ADME-Tox
    • 4.5.3 Current and Future Use of Assay Instruments
    • 4.5.4 Importance of Phenotypic Screens
    • 4.5.5 ADME-Tox Screens
    • 4.5.6 Use of ELISA in Secondary Screening
    • 4.5.7 Need for Higher Throughput ELISA Technology
    • 4.5.8 Cell Lines Used for Cell-Based Assays for Primary Screening
    • 4.5.9 Cell Lines Used for Cell-Based Assays for Secondary Screening
    • 4.5.8 Cell Lines Used for Cell-Based Assays for HCS
  • 4.6 High Content Screening
    • 4.6.1 HCS Application in Drug Discovery
    • 4.6.2 Assays Requiring More Content
    • 4.6.3 Steps Taken to Overcome Barriers to Adopting HCS
    • 4.6.4 Top Requirements for Purchasing HCS System
  • 4.7 Microplates and Other Formats
    • 4.7.1 Formats Used for Primary Screening
    • 4.7.2 Formats Used for Secondary Screening
    • 4.7.3 Formats Used for HCS Screening
    • 4.7.4 Microplate Suppliers
  • 4.8 Detection Technologies
    • 4.8.1 Detection Technologies for Primary Screening
    • 4.8.2 Detection Method Used for Assays Screened
    • 4.8.3 Preferred Detection Technology
    • 4.8.4 Investment in Automated Patch Clamp System
    • 4.8.5 Ion Channel Screening Needs
    • 4.9 Outsourcing and Collaborations
    • 4.9.1 Outsourcing HTS Activities
    • 4.9.2 HTS Services Provided
    • 4.9.3 Decision Point to Outsource HTS Activities
    • 4.9.4 Consideration of Purchasing Services from an Instrument Vendor
  • 4.10 Budgets
    • 4.10.1 Budget for Cell-Based Assays, HCS, and ADME-Tox
    • 4.10.2 Average Expenditures and Budgets at HTS Laboratories
    • 4.10.3 Expected Changes in Category Spending
    • 4.10.4 Top Equipment Suppliers
    • 4.10.5 Evaluation of Competing Systems
    • 4.10.6 Reagent Bottlenecks
  • 4.11 Industry Forums
    • 4.11.1 Useful Journals/Publications
    • 4.11.2 Conferences Attended
  • 4.12 Success of HTS in Drug Discovery
    • 4.12.1 Leads Generated by HTS in 2010 and 2011
    • 4.12.2 Change in Percentage of Targets Which Generate Leads
    • 4.12.3 IND Applications Filed
  • 4.13 Promising New Tools for HTS
    • 4.13.1 Improvement to Small Molecule Screening
    • 4.13.2 Technologies that Fulfilled their Promise
    • 4.13.3 Impact of Large Molecule Research
    • 4.13.4 Unmeet Needs in HTS
    • 4.13.5 Trends That Will Shape HTS

Chapter 5: ANALYSIS OF COMPANIES SUPPLYING HTS PRODUCTS AND SERVICES

  • 5.1 Supplier Company Respondents
    • 5.1.1 Suppliers Participating in this Survey
    • 5.1.2 Major Acquisitions
    • 5.1.3 Type of Supplier Company
    • 5.1.4 Products and Services
    • 5.1.5 Expansion of Product Offerings Outside HTS
    • 5.1.6 Organizational Changes at Supplier Companies
    • 5.1.7 Changes at Supplier Companies by Activity
  • 5.2 Customers and Customer Requirements
    • 5.2.1 Suppliers' Observations of Customer's Organizational Changes
    • 5.2.2 Effect of Customer Organizational Changes
    • 5.2.3 Suppliers' Observations of Customers' Technical Changes
    • 5.2.4 Assay Development Focus
    • 5.2.5 Top Reasons Customers Choose a Supplier
    • 5.2.6 Important Product Attributes
  • 5.3 Observations of HTS Product Trends
    • 5.3.1 Top Classes of Target Reagents Sold
    • 5.3.2 Rating of Customers Assay Approach to Drug Discovery
    • 5.3.3 Customers' Use of Profiling Information
    • 5.3.4 Opinion of Label-Free Methods and Assays
    • 5.3.5 Impact of Large Molecule Therapeutics Research
    • 5.3.6 Effect of Standard Microplate Formats on Screening Operations
    • 5.3.7 Microplate Sales Mix by Well Format
  • 5.4 Sales and Marketing
    • 5.4.1 New Customer Acquisition
    • 5.4.2 Most Effective Trade Shows
    • 5.4.3 HTS Supplier Competitive Challenges
    • 5.4.4 Purchasing Trends in Academic, Contractor and Innovator Organizations
    • 5.4.5 Most Attractive Market and Product Segments
    • 5.4.6 Areas of Strong and Weak Pricing
  • 5.5 Supplier Customer Base
    • 5.5.1 Number of HTS Customer Labs Served
    • 5.5.2 Estimate of Number of Worldwide HTS Labs
    • 5.5.3 Supplier Sales Revenue by Region
    • 5.5.4 Observed Changes in Regional Markets
    • 5.5.5 HTS Product and Service Sales by Industry Segment
    • 5.5.6 HTS Product and Services Revenue by Category
  • 5.6 Future Trends
    • 5.6.1 Suppliers' Expectation of Market Growth
    • 5.6.2 Customers Outsourcing Drug Discovery
    • 5.6.3 Major Technology Trends in HTS
    • 5.6.4 Disruptive Technologies for HTS

Appendix A: Coded Write-Ups of Interviews with 42 HTS Directors

Appendix B: Descriptions of Suppliers New HTS Products and Services

Appendix C: Interview Guide for Pharmaceutical and Biotechnology Companies, Non-Commercial Laboratory Respondents and Contract Research Organizations

Appendix D: Interview Guide for HTS Supplier Company Respondents

Back to Top